Co-Diagnostics Posts 30% Stock Surge After Q1 Assay Breakthroughs and Legal Win
By ATTN Desk · Editorial oversight: Sean Han
Introduction
CO DIAGNOSTICS INC (NASDAQ: CODX) is a Salt Lake City–based molecular diagnostics company specializing in real-time polymerase chain reaction (PCR) technologies. Since its founding in 2013, Co-Dx has developed portable PCR platforms and chemistry—powered by its proprietary Co-Primers® technology—to facilitate on-site and at-home testing for infectious diseases.
| Ticker | Exchange | Price (USD) | Change | Volume |
|---|---|---|---|---|
| CODX | NASDAQ | 0.3450 | +29.99% | 22,102,674 |
Corporate Structure
Co-Dx employs between 51 and 200 professionals within research, manufacturing, regulatory affairs, and commercial functions. The company’s headquarters in Utah houses its molecular diagnostics R&D center, where its scientists design assays targeting DNA and RNA markers. Co-Dx’s offerings include in vitro diagnostic (IVD) products, research-use-only kits, and vector control solutions.
Molecular Diagnostics by CDC
Developments and News
On May 8, 2025, Co-Diagnostics reported its financial results for the quarter ended March 31, 2025. Management noted advancements in developing four assays—tuberculosis, respiratory multiplex, HPV multiplex, and COVID-19—for its upcoming Co-Dx PCR Pro point-of-care instrument. A conference call and webcast were conducted on the same day to discuss these developments and outline regulatory submission timelines.
On March 6, 2025, the United States District Court for the District of Utah granted summary judgment in favor of Co-Dx in the Section 10(b) securities class action (Gelt Trading, Ltd. v. Co-Diagnostics, Inc.). The court determined that the alleged corrective disclosures did not establish loss causation, resulting in the dismissal of the case.
Co-Dx’s CEO Dwight Egan participated in a discussion on March 3, 2025, at the Silicon Slopes Summit, along with Nasdaq Listings host Kristina Ayanian. Additionally, on February 24, 2025, a joint venture, CoSara Diagnostics Pvt. Ltd., hosted a holistic cancer awareness lecture series, indicating Co-Dx's efforts in expanding into oncology diagnostics.
Financial and Strategic Aspects
For Q1 2025, Co-Dx emphasized non-GAAP adjusted EBITDA as a measure of operational performance, excluding certain items such as depreciation, stock-based compensation, and fair-value adjustments. While specific revenue and net income figures were not disclosed in the press release, management reiterated its commitment to operational efficiency and advancing clinical evaluations. Regulatory submissions for the four lead assays are projected to begin in the upcoming quarters, preparing the Co-Dx PCR Pro platform for phased market entry.
Strategically, Co-Dx is utilizing its magnetic-induction qPCR cycler (the Co-Dx Box™) to serve laboratories, point-of-care facilities, and end-users at home. The compact design requires no optical alignment and integrates with Co-Dx Logix Smart® and Vector Smart® tests.
Market Position and Industry Context
The global molecular diagnostics market is expanding due to increased demand for rapid and accurate infectious disease testing. Co-Dx has sold over 34 million real-time PCR tests globally, competing with established PCR providers by emphasizing portability, affordability, and cloud-enabled data management. Its focus on multiplex assays for TB, HPV, and respiratory pathogens targets both developed markets and underserved regions, where on-site diagnostic capability remains limited.
tl;dr
On May 8, 2025, CO DIAGNOSTICS INC reported Q1 financial results, highlighting progress on four PCR assays—tuberculosis, respiratory multiplex, HPV multiplex, and COVID-19—for its PCR Pro platform. A court ruling on March 6, 2025, dismissed the company’s Section 10(b) class action, alleviating a legal concern. Co-Dx plans to initiate clinical evaluations and regulatory filings in the second half of 2025, aiming for a phased market launch of its portable, cloud-connected PCR system.